Boaz Kurtis
Dr. Boaz Kurtis is the Chief Executive Officer of Intersect Diagnostics, a translational biomarker discovery laboratory serving the life science industry. Boaz founded Intersect to fill unmet needs in precision drug development for oncology and immune-mediated disorders. As a molecular pathologist, Boaz’s strategic focus for Intersect is to advance applications of novel spatial technologies that integrate digitized histopathology with quantifiable, ultra-highplex proteomic and genomic biomarker assessment.
Prior to founding Intersect, Boaz held roles of increasing responsibility at Nasdaq-listed Cancer Genetics, Inc. (now part of Interpace Biosciences, Inc.), serving most recently as Vice President for Molecular Pathology. In that capacity, he led the company’s molecular diagnostics program for the biopharma and biotech industry in part by integrating next-generation sequencing data with immunohistochemistry.
Earlier in his career, Boaz spent five years training cardiac electrophysiologists on 3-D electroanatomic mapping for Biosense Webster, Inc. (a Johnson & Johnson Company), the world’s leading manufacturer of heart rhythm mapping and navigation systems.
Boaz holds a B.A. in history from the University of Maryland and an MD from Tel Aviv University’s Sackler School of Medicine. He resides in Northern New Jersey.